Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Cash from Financing Activities data on file, last reported at $6.1 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $6.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (changed N/A YoY), and the FY2025 annual result was $18.6 million, up 3.82% from the prior year.
• Cash from Financing Activities improved to $6.1 million in Q1 2026 per VVOS's latest filing, from $4.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $7.4 million in Q2 2024 and troughed at $2.8 million in Q3 2025.
• A 4-year average of $4.7 million and a median of $3.8 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 50.58% in 2024, then jumped 41.94% in 2025.
• A 4-year view of Cash from Financing Activities shows it stood at $3.6 million in 2023, then decreased by 14.41% to $3.1 million in 2024, then soared by 41.94% to $4.3 million in 2025, then surged by 40.92% to $6.1 million in 2026.
• Business Quant data shows VVOS's Cash from Financing Activities at $6.1 million in Q1 2026, $4.3 million in Q4 2025, and $2.8 million in Q3 2025.